Tomek Sandra, Manegold Christian
Department of Medicine I, University Hospital Vienna, Austria.
Curr Opin Oncol. 2003 Mar;15(2):148-56. doi: 10.1097/00001622-200303000-00006.
This paper covers the outcome of previously conducted clinical trials on chemotherapy for malignant pleural mesothelioma and presents data from recent phase II and phase III trials. In contrast to conventional cytotoxic drugs, which have barely produced response rates exceeding 30%, recently introduced chemotherapeutic agents and their combinations promise to be more effective. Especially pemetrexed has yielded response rates of up to 45% in combination with platinum compounds. Furthermore, raltitrexed-oxaliplatin has shown promising activity and gemcitabine was found to improve quality of life in patients with malignant pleural mesothelioma when applied as a single agent or in combination with cisplatin. Based on robust phase III study results, pemetrexed-cisplatin may soon be considered with chemotherapy for this aggressive disease.
本文涵盖了先前进行的恶性胸膜间皮瘤化疗临床试验的结果，并展示了近期II期和III期试验的数据。与传统细胞毒性药物（其有效率几乎未超过30%）相比，最近引入的化疗药物及其组合有望更有效。特别是培美曲塞与铂类化合物联合使用时有效率高达45%。此外，雷替曲塞-奥沙利铂已显示出有前景的活性，并且吉西他滨在单独使用或与顺铂联合使用时被发现可改善恶性胸膜间皮瘤患者的生活质量。基于有力的III期研究结果，培美曲塞-顺铂可能很快会被视为针对这种侵袭性疾病的化疗方案。
